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How to appropriately extrapolate costs and utilities in cost-effectiveness analysis  
 
 
Abstract 
Costs and utilities are key inputs into any cost-effectiveness analysis (CEA). Their estimates are typically 
derived from individual patient level data collected as part of clinical studies whose follow up duration is often 
too short to allow a robust quantification of the likely costs and benefits a technology will yield over the entire 
patient's lifetime.   
 
In the absence of long-term data, some form of temporal extrapolation - to project short-term evidence over a 
longer time horizon - will be required.  Temporal extrapolation inevitably involves assumptions regarding the 
behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence. 
Unfortunately, the implications for decisions made on the basis of evidence derived following this practice and 
the degree of uncertainty surrounding the validity of any assumptions made are often not fully appreciated. 
The issue is compounded by the absence of methodological guidance concerning the extrapolation of non-
time to event outcomes such as costs and utilities. 
 
This paper considers current approaches to predict long-term costs and utilities, highlights some of the 
challenges with the existing methods, and provides recommendations for future applications. It finds that, 
typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and 
utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to 
both time and patients' characteristics. Furthermore, costs and utilities have often been modelled to follow 
the dynamics of the associated time-to-event outcomes. However, cost and utility estimates may be more 
nuanced, and it is important to ensure extrapolation is carried out appropriately for these parameters.  
 
Key points 
1. Need to consider how costs and utilities are extrapolated in a cost-effectiveness model 
2. There is no guidance on methods for extrapolating costs and utilities 
3. Existing applications use various approaches with little justification 
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Introduction 
In many countries decisions concerning the adoption of new health technologies (e.g. drugs, diagnostics) are 
informed by evidence relating to the cost effectiveness of competing interventions [1]. The range of costs 
considered in the assessment of cost-effectiveness will depend on the perspective of the analysis[2], with a 
health service perspective implying a more narrow range of costs than a societal perspective. In terms of 
relevant outcomes(health benefits), many national and regional decision makers require that outcomes reflect 
both mortality and morbidity effects, with the latter typically measured using the EuroQol five dimension (EQ-
5D) instrument [3],  a  generic preference-based measure of health related quality of life (HRQoL or utility), 
which can be used to generate quality adjusted life years (QALYs).   
 
An appropriate time horizon to determine whether a health technology is cost-effective is the timeframe over 
which costs and/or health outcomes may be expected to differ between interventions.  In many 
circumstances, this timeframe is the patient's lifetime, particularly where there are mortality effects. In 
England and Wales, for instance, the National Institute for Health and Care Excellence (NICE), which issues 
guidance on which treatments should be paid for by the NHS, stipulates that the time horizon of the cost-
effectiveness analysis (CEA) should be sufficient to reflect important cost and outcome differences between 
the technologies being compared [4]. Similar guidance exists for other countries such as TLV in Sweden[5] and 
IQWiG in Germany[6].  
 
Unfortunately it is extremely unlikely that clinical evidence will exist for the full period over which differences 
in costs and QALYs are expected to occur, and it is even less likely that to be the case for resource use, costs 
and utilities
a
.  Thus, in many circumstances, some form of modelling will be necessary to project short-term 
outcomes over the lifetime of the patients [7].  This practice requires appropriate methodology and a set of 
assumptions, and it is important that the additional uncertainty in the results is fully recognised when such 
analyses are used to inform reimbursement decisions. 
 
There have been efforts to produce guidance on the appropriate methods to extrapolate effectiveness data, 
particularly time to event data [8, 9], however, there is very little advice available concerning the extrapolation 
of resource use, costs and utilities.  In this paper we argue that it is not appropriate, and potentially 
misleading, to assume that these quantities follow the same dynamics as the time-to-event parameters in the 
model.   
 
Given the lack of guidance on how to extrapolate resource use, costs and utilities, a priori we expect there to 
be some variability in approaches used in the applied literature.  Since the method chosen to extrapolate may 
                                                          
a
 This is because many clinical studies are  W first and foremost - designed to satisfy the requirements of 
licensing authorities (e.g. FDA, EMA) and these do not consider the collection of information relevant to 
reimbursement authorities.  
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influence the cost effectiveness results, the estimates of decision uncertainty and ultimately adoption 
decisions, there is potential cause for concern [10].  This paper considers how resource use, costs and utilities 
have been extrapolated in cost-effectiveness modelling, using examples from the literature. Methods 
employed are categorised and critiqued in terms of their strengths and weaknesses, discussing the 
implications of any shortcomings. It is recognised that resource use and unit costs, combined to derive costs, 
may have some differences. While estimates of resource use are typically obtained from experimental data, 
the unit costs assigned to each item of resource use are usually derived from an external source such as 
hospital records or national statistics [11]. In addition, the nature of long-term uncertainty over resource use 
and unit costs may be quite different, as is how we estimate them over the short-term. For ease of 
explanation, however, forthwith they are collectively referred to as costs, and any differences in 
methodologies are discussed when apparent.  
 
Assessing the methodologies used to extrapolate costs and utilities 
In extrapolating over a longer time horizon, it is typical for cost-effectiveness models to utilise data sources 
external to the effectiveness evidence, to provide inputs for costs and utilities. These external sources of 
evidence include observational studies such as - for instance - that used in Garside et al[12], which describes a 
quality of life study used to determine utilities for a Markov model specifying health states according to 
disease severity. Many models utilise previously published estimates of costs and utilities reported in other 
economic models. There are also examples of studies which have used expert opinion [13, 14] or analyst 
assumptions[15, 16]. For many cost-effectiveness models there is insufficient information reported to reliably 
gauge the methods used to extrapolate healthcare costs and utilities for health states and clinical events, 
including  W for example  W Glazener et al[17], where it is not clear how costs observed at 2 years within the 
PROSPECT study were extrapolated over the 5 and 10 year time horizons.. In such instances the focus seems to 
be on describing extrapolation methods used for the effectiveness evidence while glossing over the 
assumptions and methods used to extrapolate costs and utilities, let alone assessing the implications of these 
assumptions in term of any decision uncertainty.  
 
Data available to extrapolate costs and utilities 
The extent to which the analyst will be able to quantify any time dependency in costs and utilities will depend 
on the data available.  Ideally, access to medium to long term individual patient level data can facilitate such 
an investigation, therefore in understanding the methodologies that have been employed, distinctions can be 
made where patient level data or aggregate (or summary study-level) data were used to populate a cost-
effectiveness model.  
 
Cost effectiveness modelling employing aggregate data 
The majority of cost-effectiveness models that make use of summary study-level or aggregate data estimates 
to quantify costs and utilities, appear to make the assumption that these parameters are homogeneous (with 
respect to time and patients characteristics), extrapolating their values using simple assumptions. These 
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quantities are often posited to follow the health states or clinical events specified by the effectiveness 
evidence, which means that estimates of long-term costs and utilities are (implicitly) dictated by how ƉĂƚŝĞŶƚƐ ?
transitions between health states and event rates are estimated and modelled, both, over the short-term 
(observed period) and long-term (unobserved period)[18].  
 
Such aggregate data is typically used within a state-transition model structure [19], although examples can be 
found also within discrete event cost-effectiveness models [20]. The impetus for this approach is often 
dictated by the fact that (a) costs and utilities are only available as a single summary study-level data point, or 
(b) even when multiple study-level observations are available they cannot be adequately synthesised [21]. 
There are, however some notable exceptions, which include recent work on the impact of osteoporosis 
fractures [22] and chronic kidney disease [23]. In the absence of patient level data, time can still be used as a 
predictor of outcomes (costs, utilities), for example using regression covariates for age or time-dependent 
covariates[24-28], where these are available. 
 
Where models chose to mimic the disease process by means of changes in clinical status, which is often 
measured in terms of condition specific clinical (or patient reported) outcomes, the assumption behind this 
practice is that these outcomes are more accurate in representing (and more sensitive to) changes in disease 
status[18, 29]. In cases where costs and utilities are a function of the health states defined within the model, 
to assess the appropriateness of the methods used to extrapolate these quantities one must understand how 
appropriate these condition-specific outcomes are in the first instance. For example there has been much 
discussion on the use of functional capability scores such as the Health Assessment Questionnaire (HAQ) and 
its use in modelling the cost-effectiveness of inflammatory musculoskeletal conditions[18].   
Cost effectiveness modelling employing individual patient data (IPD) 
In theory, IPD datasets are useful inputs into cost-effectiveness models and provide more accurate data on 
changes in cost and utilities over time. Hatswell, et al[30] showed that an analysis of patient level data is 
essential prior to populating an economic model. In many oncology models, progression status is used to 
define health states in the model and utilities/costs are assigned to these states.  In the example of metastatic 
melanoma, Hatswell, et al[30] determined utilities according to progression status and time to death and 
showed that the use of time to death gave similar or better estimates of the original data when used to predict 
patient utility in the IPD dataset.  
 
Previous studies have shown that age is a predictor of increased mean costs[31, 32]. Analysis of individual 
patient level data (IPD) has explored this relationship.  An example is the Randomised Intervention Treatment 
of unstable Angina (RITA-3) trial[ 27] , which compared an early interventional strategy (coronary 
arteriography and myocardial revascularisation as clinically appropriate) or a conservative management 
strategy in patients admitted with an episode of cardiac chest pain associated with documented evidence of 
coronary heart disease.  Resource use data, hospital visits, procedures and medications, were collected over a 
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5 year follow up and multiple regression analysis of the 5 year follow up data from the RITA-3 trial[33] showed 
that, on average, costs increased by £737, for every 10 years over age 60.    
 
When using IPD on costs and utilities directly from a trial that has also provided effectiveness data to model 
the disease prognosis, the distinction between those analyses that do not account for time (e.g. cross sectional 
analyses at a fixed time point) and those analyses that explicitly model time, such as longitudinal and time-to-
event studies, is crucial. Many models use cross-sectional data to estimate the relationship between an 
outcome (e.g. cost or utility) and its predictor (e.g. a clinical measure of disease severity). It could be argued 
that if one is interested in analysing IPD to derive input parameters to model long term costs and utilities, 
access to longitudinal outcome dataset is preferred, however in some instances longitudinal data does not 
ensure that any differences over time are captured, depending on the length of follow up[34].   
 
Cross-sectional data can provide information about differences in costs and utilities for patients as a function 
of age as well as disease stage/health state, provided that the sample includes sufficient patients across the 
range of ages and disease stages relevant to inform the economic model. In addition analysts should perform 
analyses which account for trends over time and apply the data appropriately in the economic model. The 
ĐƌŽƐƐƐĞĐƚŝŽŶĂůĚĂƚĂŵƵƐƚĂůƐŽƌĞĨůĞĐƚĂƉĂƚŝĞŶƚ ?Ɛcharacteristics, where it is likely to influence costs and 
ƵƚŝůŝƚŝĞƐ ?ĨŽƌĞǆĂŵƉůĞŚĞĂůƚŚƐƚĂƚĞƐĚĞĨŝŶĞĚƵƐŝŶŐǁĞŝŐŚƚĐĂƚĞŐŽƌŝĞƐ ?ǁŚĞƌĞĂŶŝŶĚŝǀŝĚƵĂů ?ƐƉƌĞǀŝŽƵƐǁĞŝŐŚƚŝƐ
likely to have an impact on their future risk of events, including diabetes.  
 
Predominately, IPD has been utilised to extrapolate costs and utilities, where outcome data are available at 
multiple follow up points, e.g. HAQ for rheumatoid arthritis and psoriatic arthritis [24-28, 35].  In these 
examples condition specific outcomes are extrapolated using appropriate methodology and the resulting costs 
and utilities derived using mapping algorithms. Regression models using data from a single randomised 
controlled trialcollecting HAQ and/or Psoriasis Area Severity Index (PASI) and EQ-5D or costs (relating to HAQ 
or PASI) have been used to represent the association between HAQ/HAQ+PASI score, for instance, and EQ-5D 
or costs[24-28, 35]. Time dependency in the EQ-5D is then modelled indirectly as function of the change in 
longitudinal outcomes over time.  Unfortunately none of these models have also controlled for the covariate 
age, which would have facilitated the incorporation of the population ageing process.  It is possible that some 
of this will be implicitly captured by the declining HAQ score over time for instance, i.e. those with worse HAQ 
scores are likely to be older (however the relationship is unlikely to be exact). Similar approaches have been 
used for other degenerative conditions, such as advanced macular degeneration (AMD)[36], where regression 
analysis has been employed to relate responses to the Health Utilities Index (HUI)3 questionnaire for 209 
individuals with AMD to both their visual acuity (VA) status and age. Results from this linear regression model 
were then used in a cost-effectiveness model to predict utility values (accounting for sampling uncertainty in 
the estimated parameters) for specific health states in the decision model. A separate scenario using another 
non-age adjusted utility algorithm was also used in a sensitivity analysis. 
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Regardless of whether data is available from a cross sectional or longitudinal study, in situations where utilities 
and costs come from patient level data outside the trial, it is imperative to explore whether (and, if possible 
adjust for) any differences in patient characteristics between the external data set and trial population. Explicit 
consideration of any differences is not typically undertaken, and more often than not simple sensitivity 
analysis will instead be employed, for example increasing costs to a specified amount to reflect a more severe 
case mix modelled in the analysis. For example in a recent model developed as part of a NICE appraisal for 
psoriatic arthritis, health state costs for patients experiencing more extensive psoriasis were increased, under 
the expectation that they would utilise more expensive treatments[37]. 
 
Categorisation of methods to extrapolate costs and utilities 
In working towards an understanding of the approaches that have been used to extrapolate costs and utilities, 
these can be categorised as two types. First, it is possible to extrapolate these outcomes directly from the trial, 
without the need to use either a decision model or external data. The study published by the US National 
Emphysema Treatment Trial Research Group[38] is one such example. To estimate long-term cost-
effectiveness, trend lines were fitted to monthly costs and Quality of Well-Being scores observed during the 
third year of follow-up. These trends were then projected over the lifetime of the model[38].  
This method is distinct from the use of IPD to populate a cost-effectiveness model, and this direct 
extrapolation from a trial could employ the use of either aggregate or patient level data. This approach is more 
commonly used for extrapolating costs, rather than utilities. This is often because there is no specific process 
to drive long term costs that could be modelled and datasets used to determine clinical effectiveness typically 
contain few repeated measurements over time for each patient (e.g. between two and five assessments), 
which make it difficult to fit complex longitudinal event history models.  
 
In the second type, models are used to estimate the events/processes which are then used to determine 
costs/utilities, either because these data were not collected in the trial or because the analysts were seeking to 
be more explicit about what drives these costs/utilities in the long term. The methods used in the modelling 
approaches are categorised in Table 1 and summarised in the sections below along with selected examples for 
each of the approaches. 
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Table 1: Methods used to extrapolate costs and utilities in cost-effectiveness models 
Method Principles Advantages Disadvantages 
Selected 
examples 
Profiles 
Fixed estimate 
(profile) of costs or 
utilities attached to 
short term events 
Easy to implement 
Does not directly 
specify the process 
by which these were 
achieved 
Difficult to 
disentangle if there 
are any changes 
over time 
incorporated 
Grant, et al  
[39] 
McKenna et al 
[40] 
Constant values 
Fixed cost or utility 
value applied to a 
specific health 
state. Often the 
same value is used 
for each of the 
comparators. 
Easy to implement 
and find data to 
populate 
Does not typically 
account for the 
impact of an ageing 
population 
Assumes the 
treatment effect is 
homogeneous with 
respect to time. 
de Vries[41]  
Keating, et 
al[42] 
Constant marginal 
change to moving 
baseline 
Constant change in 
cost or utility is 
applied to an ageing 
population baseline 
value.  Uses additive 
or multiplicative 
approach, the latter 
reflecting changes 
in costs or utilities 
over time. 
Reflects, for 
example, an ageing 
population, or any 
other parameters 
thought to change 
over time such as 
treatment effect. 
Additive approach 
assumes 
homogenous change 
in costs and utilities 
over time. Data may 
not be available to 
employ a 
multiplicative 
approach 
 
Harrison, et 
al[43] 
Stevenson et al 
[44] 
Regression approach 
This uses external 
data to generate an 
algorithm linking 
disease specific 
measures to costs 
or utilities. 
Can incorporate 
time explicitly using 
age as covariates 
for example. 
Requires patient 
level data for 
estimation. 
Uncertainty in the 
prediction of 
costs/utilities should 
be reflected. 
Loveman et al 
[25] 
Henrikkson, et 
al[45] 
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Profiles of costs or utilities 
In some instances, rather than specifying a formal model with health states assigned costs and utility values, 
authors have applied a fixed estimate (profile) to short term events without directly specifying the process by 
which these were achieved. In the REFLUX model[39], initially a state based model was specified which 
attached a utility score following (a) medical management, (b) successful laparoscopic surgery and (c) 
unsuccessful laparoscopic surgery (on medication). This meant that the probabilities of being in these states 
had to be specified. In a later version of the model this restriction changed so that the trends in costs and 
utilities observed at the end of the REFLUX trial were simply extrapolated to longer time horizons, without the 
need to attach these to specific health states[39]. Sensitivity analysis was conducted to explore alternative 
assumptions regarding these profiles over the model time horizon. 
 
McKenna et al [40] used alternative approaches to inform the duration of quality of life benefits over time in 
the model, in the absence of suitable trial estimates for the duration of treatment benefits. Formal elicitation 
techniques were used to determine the sustained duration of utility improvements seen after 1 year in the 
EECP trial. Elicitation of clinical experts ? opinions was used to estimate the probability of patients experiencing 
a sustained health benefit beyond the trial period. Therefore the utility difference isn't attributed to a set of 
discrete events/states in the model and instead the direct utility differences are used within the extrapolation.  
 
Constant costs or utilities applied to health states or events 
For models that attach a cost and utility to a specific health state or event within a model, the majority do this 
by applying a constant cost and utility.  Often this is undertaken by implementing a Markov model and as such 
the same approach was used for both baseline (i.e. control group) and treatment effect. Any treatment effect 
is derived from the modelled differential event rates. Patients in a given health state (or experiencing an 
event) require a fixed amount healthcare resources (to generate fixed costs) and experience a given utility 
value (dis-utility in the case of a clinical event) for the entire cycle length. This method does not typically 
account for the impact of an ageing population on the baseline cost and utility and assumes the treatment 
effect to be homogeneous with respect to time; however it is important to consider if the cost or utility 
applied to a particular health state is representative over the entire model. For example, several cancer studies 
estimate a single utility value for progression, which estimated from patients at the point at which they 
progress or are close to progressing [46]. However, this assumes that the utility is homogeneous with respect 
to time and in many cases, there may be a non-linear relationship between time post-progression or time from 
death and utility [47]. 
 
In de Vries, 2016[41] a model was developed to assess the cost-effectiveness of delaying end stage renal 
disease.  To generate survival estimates, data from the Dutch Renal Registry was utilised to estimate the 
age distribution and survival for renal replacement therapy (RRT)[41] and thus generate age-dependant 
remaining life expectancy after RRT. Although age specific survival estimates were generated, costs and 
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utilities were assumed constant post RRT. Similarly in Keating, et al[42], which assessed the cost-
effectiveness of surgically induced weight loss for management of type 2 diabetes, a constant 
maintenance cost was applied for each year that the patients remained alive.  
 
 
Constant increment/decrement applied to changing baseline cost or utility  
In this approach a constant decrement or increment in cost or utility is applied to an ageing population 
baseline value (an additive approach). The decline occurs because of increased co-morbidities affecting these 
outcomes in later life.   Failure to capture this decline/increase in costs or utilities may produce incorrect 
estimates of cost and QALYs. For those interventions with a mortality effect, this will also bias the comparisons 
between modelled strategies, as those patients surviving till later in the extrapolation period will be assigned a 
higher utility then can be expected according to their age. In this instance treatments reducing mortality, for 
example those reducing myocardial infarction related deaths, which are primarily in those 65+, are likely to 
overestimate QALYs.  
 
In the case of utility values, this is usually done using the UK population norms from the EQ-5D index values 
[48].  As population mean utility values decline over time, the utility associated with the membership of a 
particular health state will also decrease over time.  Similarly for costs, a constant incremental cost for the 
intervention (or control) may be applied to an increasing baseline cost, reflecting the fact that healthcare costs 
can rise as the population ages. Many cost-effectiveness models employ this approach for utilities but few 
utilise this methods for costs, instead assuming a constant cost over time.  
 
Alternatively a multiplier can be applied differentially throughout the model in an attempt to reflect changes in 
costs or utilities over time. Stevenson et al [44] apply a different multiplier within the first year and a separate 
multiplier that applies for the remaining years of the simulation. A utility multiplier is combined 
multiplicatively with the general population utility to provide an estimate of the utility for patients in that 
state, and results in the absolute dis-utility becoming less as a person ages and their underlying utility lower.  
 
In Harrison, et al[43] long term utilities were based on differences between the comparators observed at 6-
months, however, rather than assuming that the differences were maintained over the lifetime, it was 
assumed that these differences diminished over time, using linear interpolation.   
 
Regression approach 
A regression type approach can be adopted [25] to derive costs or utilities for health state estimates from 
external data sources. In Loveman et al [25] a regression analysis was used to infer the reduction of utility over 
time and to model utility beyond the last observation of the trial. Baseline utility was taken as the midpoint 
between the two arms of the trials. To estimate the utility at a given number of days from baseline, a 
regression model was specified that incorporated a utility decrement multiplied by the number of days from 
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baseline (the time element). It is not clear if any uncertainty in the estimated coefficients was incorporated 
into the model or if other functional forms were tested. 
 
Appropriateness of methods used to extrapolate cost and utilities 
The more simplistic methods of assigning costs and utilities within a cost-effectiveness model, such as profiles 
or constant values, appeal on the basis that they are simple to implement and do not rely heavily on data that 
is often difficult to come by. They do however impose a number of limitations. Such methods often assume 
that costs and utilities are homogeneous with respect to time, with time relating to an ŝŶĚŝǀŝĚƵĂů ?Ɛ age within a 
model but also the time horizon for effectiveness of any treatments. As discussed, there are reasons to believe 
that costs and utilities may change as the population of the model ages and there is also reason to believe that 
the effectiveness of any treatments may diminish over time, or in the very least we are less certain about 
effectiveness over the longer term.  
 
Whichever sources of data are available, and whichever method is used to extrapolate costs and utilities, it is 
important to consider how accurate the estimates are likely to be and employ measures to test for validity and 
characterise any uncertainty. Regression approaches can include an estimate of parameter uncertainty and 
may also be used to explore different functional forms for the statistical model that links covariates to 
outcomes. It is also advantageous to calibrate these regressions to external data to assess validity [49]. 
Supplementing an extrapolation with external evidence can improve the external validity of the predictions. 
Where multiple scenarios are available for extrapolation it may be useful to explore combining alternative 
scenarios, through Bayesian model averaging [50]. Of course, these scenarios only reflect uncertainty in the 
short term (observed) data, rather than the extrapolated (unobserved) period but similar methods can be used 
to average predictions under different extrapolation model assumptions and weight these using expert 
judgements. 
 
A recent report by the NICE decision support unit [51] considered the use of utilities in decision models and 
although the issue of extrapolation was not its primary focus, the uncertainties arising when using lifetime 
horizons to accrue QALYs was discussed. This report recommended that when extrapolating beyond an 
observation period (in which utilities have been captured) efforts should be made to supplement the utilities 
with external evidence to allow for changes over time in patients quality of life, such as ageing and increased 
co-morbidities[52]. The document also indicates that it would be appropriate to supplement the evidence on 
utilities with baseline data from the general public. This approach matches the approach described above, 
which applies a constant utility decrement to a declining baseline utility score.  In utilising external utility data, 
a full description of the patient population and any assumptions made should be given.  There is some 
evidence to suggest that in certain circumstances the use of general population data as baseline utilities might 
not be appropriate [51].  This is a particular issue for conditions with a high prevalence in the general 
population. The baseline utilities (usually below 1) are therefore likely to already include the utility decrement 
associated with this condition. 
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Discussion 
Often a rather simplistic approach to extrapolation of costs and utilities is employed in the cost-effectiveness 
literature, with many cost-effectiveness models assuming a constant utility/utility decrement over the 
extrapolation period, although they may incorporate time variations for effectiveness parameters.   
Long-term predictions of these outcomes are primarily driven by the methods used to extrapolate clinical 
outcomes or health states with little consideration given to the appropriateness of assumptions for costs and 
utilities. Yet there is evidence to suggest that any differences in costs and utilities are not constant over time. 
Models assessing the cost effectiveness of competing alternatives fail to reflect this fact in choosing an 
appropriate extrapolation technique. This is likely to be driven by a lack of literature on the extrapolation of 
costs and utilities and a lack of knowledge of the appropriate methods to use. 
 
From a practical point of view, the extent to which the analyst will be able to quantify any time (or covariate) 
dependency in utilities and costs will primarily depend on the data available.  Ideally, access to medium-to-
long term IPD can facilitate such an investigation, however good (repeated) cross sectional data sets can 
suffice if these cover a significant population of patients and methods are employed to sample across relevant 
characteristics.  
 
When using IPD on costs and utilities derived directly from the trial that provided effectiveness data to model 
the disease prognosis, it is important to distinguish between those analyses that do not account for time (e.g. 
cross sectional analyses at a fixed time point) from those analyses that explicitly model time, such as 
longitudinal and time-to-event studies (i.e. effect of health state and time). It could be argued that if one is 
interested in analysing IPD to derive input parameters to model long term costs and utilities, access to 
longitudinal outcome dataset is essential. Unfortunately costs and utilities are almost invariably collected at 
fixed time points during the study follow up period. When modelling longitudinal cost/utility data it would be 
desirable to analyse these alongside some time-to-event variable (e.g. occurrence of clinical events with 
concurrent measure mean of cost/utility) to estimate the impact that these events have on costs and/or 
utilities/HRQoL. One recent example by Briggs, et al, 2016[53] showed that there were large utility decrements 
after clinical events in patients with secondary hyperparathyroidism.  The absence of joint information makes 
difficult to explicitly model specific event history processes that affect costs and HRQoL. 
 
It should be noted that the collection of cost and utility data prospectively within studies is often difficult. 
Unfortunately cost and utility data available from randomised trials and observational data, is often besieged 
with missing data. Such data is unlikely to be missing completely at random and it is important to consider how 
missing data may bias summary estimates of costs and utility from these studies.  There are examples of 
studies where the methods used to impute for missing data has had a large impact on the costs generated[54]. 
There are, however, implications for improving the collection of data to facilitate cost-effectiveness modelling 
in studies. It is not clear how this should be done most efficiently and if the benefits out way the risks, such as 
patient withdrawal or failure to recruit sufficient numbers.  
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The challenge of capturing changes in costs over time also relates to the inclusion of future costs within cost-
effectiveness models. These are costs that may be related or unrelated to a specific condition.  Under current 
NICE guidance, all related costs should be included in the analysis using an appropriate time horizon (where 
there a mortality effect this should be a lifetime). NICE guidance on technology appraisals[4] states that  ?costs 
related to the condition of interest and incurred in additional years of life gained as a result of treatment 
should be included in the reference-case analysis. Costs that are considered to be unrelated to the condition or 
technology of interest should be excluded ?.  By extending the remit of costs to include unrelated costs, which 
many authors have argued is appropriate to do [55-57], the practical challenge of appropriately estimating any 
changes in costs over time is magnified, by the simple fact of having more relevant costs to include in the 
calculation of total costs.  
 
Key is the exploration of any uncertainty in extrapolating costs and utilities. Reflecting such uncertainties in 
any assessment of cost-effectiveness is paramount to understanding the extent to which trends in costs and 
utilities evolve drive adoption decisions. This helps to inform the extent to which efforts are made in improving 
data collection for costs and utilities. However uncertainty regarding costs and utilities may, in some 
circumstances, be distinct from other forms of uncertainty in a cost-effectiveness model. Uncertainty is 
something that we would hope to resolve with further research, if it is plausible to conduct. For costs in 
particular, however, there is a degree of uncertainty relating to prices that may not be resolved by further 
events, for example drugs going off patent [58]. Over time, societal valuation of utilities may also change 
and it is difficult to reflect these uncertainties using conventional methods such as probabilistic sensitivity 
analysis[59]. Others have used scenarios to explore the extent to which possible changes in the evidence base 
may influence adoption decision and the value of further research[58], although this still requires plausible 
ranges for any future changes. 
 
Limitations 
This paper illustrates the heterogeneity in methodology used to extrapolate costs and utilities in cost-
effectiveness models and gives examples of the approaches used. It can be postulated that different 
methodologies will generate different estimates of total costs and utilities for competing interventions, and 
thus estimates of cost-effectiveness. Without empirical evidence to support this, however, it is difficult to 
gauge the importance of the methods used to extrapolate costs and utilities in determining adoption decisions 
and estimates of decision uncertainty. An area of further research is thus to provide applied examples of the 
competing methodologies, where data, sources allow, and to explore the implications of different assumptions 
explicitly. 
 
 
Conclusions 
Typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and 
utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to 
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both time and patients' characteristics. Furthermore, costs and utilities have often been modelled to follow 
the dynamics of the associated time-to-event outcomes.  Clinical events may affect costs and utilities, but 
there are many other long term processes that are pertinent to the evolution of costs and utilities that are not 
linked to clinical events.  Examples include, relative changes in unit costs that may affect the resource use mix 
ƵƐĞĚƚŽƚƌĞĂƚĂƉĂƚŝĞŶƚ ?ŝŶĚŝǀŝĚƵĂů ?ƐĂŐĞ ?ƉƌŝŽƌĐůŝŶŝĐĂůŚŝƐƚŽƌǇ ?ƉĂƚŝĞŶƚĂĚĂƉƚĂƚŝŽŶƚŽƉĂƌƚŝĐƵůĂƌŚĞĂůƚŚƐƚĂƚĞƐĂŶĚ
changes in clinical practice over time affecting best current practice. The course of associated costs and 
utilities over time may also vary between individuals.  
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